Compare

Puma Biotechnology, Inc. vs Akebia Therapeutics, Inc. vs Arcus Biosciences, Inc. vs Arvinas, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Puma Biotechnology, Inc. PBYI	Akebia Therapeutics, Inc. AKBA	Arcus Biosciences, Inc. RCUS	Arvinas, Inc. ARVN
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	$228.37M	$236.20M	$247.00M	$262.60M
Revenue growth (YoY)	-0.9%	+47.5%	-4.3%	-0.3%
Gross margin	74.5% (computed)	83.3% (computed)	n/a	n/a
Operating margin	16.3%	9.9%	-156.3%	-45.1%
Net margin	13.6%	-2.3%	-142.9%	-30.8%
Net income	$31.11M	-$5.34M	-$353.00M	-$80.80M
EPS (Diluted)	$0.61	-$0.02	-$3.29	-$1.14
Operating cash flow	$41.80M	$67.99M	-$482.00M	-$273.80M
Free cash flow	$41.73M	$67.70M	-$484.00M	-$275.70M
Cash & equivalents	$29.64M	$184.84M	$222.00M	$142.90M
Total assets	$216.30M	$376.56M	$1.14B	$717.90M
Total liabilities	$85.96M	$343.95M	n/a	$284.00M
Shareholders' equity	$130.34M	$32.61M	$631.00M	$433.90M
Return on year-end equity	23.9%	-16.4%	-55.9%	-18.6%
Shares outstanding	50.41M	265.42M	125.30M	63.50M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Puma Biotechnology, Inc.	Akebia Therapeutics, Inc.	Arcus Biosciences, Inc.	Arvinas, Inc.
Latest	$228.37M Ended 2025-12-31	$236.20M Ended 2025-12-31	$247.00M Ended 2025-12-31	$262.60M Ended 2025-12-31
1 year earlier	$230.47M Ended 2024-12-31	$160.18M Ended 2024-12-31	$258.00M Ended 2024-12-31	$263.40M Ended 2024-12-31
2 years earlier	$235.64M Ended 2023-12-31	$194.62M Ended 2023-12-31	$117.00M Ended 2023-12-31	$78.50M Ended 2023-12-31
3 years earlier	$228.03M Ended 2022-12-31	$292.48M Ended 2022-12-31	$112.00M Ended 2022-12-31	$131.40M Ended 2022-12-31
4 years earlier	$253.16M Ended 2021-12-31	$211.65M Ended 2021-12-31	$383.00M Ended 2021-12-31	$53.60M Ended 2021-12-31